[Gta Pune City Game Free Download Full Version
Luther Lazaro
When it comes to pushing numbers, Honda lags behind other heavy-lifters like Maruti Suzuki, Hyundai, Tata, Mahindra and even newcomer Kia. With just 9,543 units sold in October 2022, Honda has nothing to write home about. It needs new and compelling products. That burden is likely to be put up by WR-V SUV that was recently launched in select South-East Asian markets.
Right off the bat, City facelift Indian version is not likely to get a similar set of updates as South-East Asian markets are getting. That one is supposedly a sportier version of the outgoing model adding a lot more character. It gets a revised bumper that holds large air dams, a larger grille, side skirts, black wheels, a spoiler, and a lot more to make it more aggressive.
India often gets skimped on the good stuff as global markets get. Speaking of good stuff, Honda City 5th generation gets a 1.0L turbo petrol engine in these markets. This is given a miss for India. This engine is held in high regard in Asian markets where it is offered. Honda might consider bringing this engine to India considering the trend shifting towards small-capacity turbo engines.
This engine displaces 1498cc and is capable of making 98 bhp and 200 Nm of torque. A 1498cc NA petrol engine is offered too, which makes 119 bhp of power and 145 Nm of torque. Petrol engine gets a choice between manual and CVT. Diesel only gets a manual, though. It rivals Hyundai Verna, Skoda Slavia, Volkswagen Virtus, and the aging Maruti Suzuki Ciaz.
Started in 2008, RushLane is India's leading auto news website. Updated daily with news on cars, bikes, motorcycles, scooters, electric vehicles, commercial vehicles, domestic sales and exports report, scoops, exclusive spy shots, as well as detailed reviews by experts. RushLane Facebook Groups - CrashLane, SpyLane, InfoLane, MemeLane, SnagLane. Join Whatsapp Group, Telegram Channel to get news / updates in your phone.
In India, dengue disease is emerging as the most important vector borne public health problem due to rapid and unplanned urbanization, high human density and week management of the disease. Clinical cases are grossly underreported and not much information is available on prevalence and incidence of the disease.
A cross sectional, stratified, facility based, multistage cluster sampling was conducted between May 4 and June 27, 2017 in Pune city. A total of 1,434 participants were enrolled. The serum samples were tested for detection of historical dengue IgG antibodies by ELISA using the commercial Panbio Dengue IgG Indirect ELISA kit. Anti-dengue IgG-capture Panbio ELISA was used for detection of high titered antibodies to detect recent secondary infection. We used this data to estimate key transmission parameters like force of infection and basic reproductive number. A subset of 120 indirect ELISA positive samples was also tested for Plaque Reduction Neutralizing Antibodies for determining serotype-specific prevalence.
Overall, 81% participants were infected with dengue virus (DENV) at least once if not more. The positivity was significantly different in different age groups. All the adults above 70 years were positive for DENV antibodies. Over 69% participants were positive for neutralizing antibodies against all 4 serotypes suggesting intense transmission of all DENV serotypes in Pune. Age-specific seroprevalence was consistent with long-term, endemic circulation of DENV. There was an increasing trend with age, from 21.6% among
Our study suggests that Pune city has high disease burden, all 4 serotypes are circulating, significant spatial heterogeneity in seroprevalence and suboptimal immunity in younger age groups. This would allow informed decisions to be made on management of dengue and introduction of upcoming dengue vaccines in the city.
Copyright: 2018 Mishra et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
In India, dengue is a reportable disease and all confirmed cases are expected to be reported to government of India through NVDCP, Delhi.[7] Recent studies using various models have suggested gross underreporting of dengue cases. It is estimated that each case reported may be multiplied by 200 to get fair estimate.[8,9]
Dengue infection results into subclinical disease in majority of the cases and clinical disease in about 25% cases. Proportions of asymptomatic, mild cases and severe cases are highly variable in different areas. Differential diagnosis between clinically similar diseases caused by DENV, Chikungunya virus and other febrile illnesses is almost impossible in resource limited countries like India. Therefore clinical surveillance data which already suffers with tremendous reporting bias is inadequate to estimate true burden of disease. In such situations, properly designed seroprevalence studies may adequately quantify and characterize the extent of transmission.
Currently there is no effective drug for treatment of dengue. Sustained effective vector control has become impractical in developing countries. Therefore vaccination has become focus of attention in management of dengue. Several vaccines are in different phases of developments and clinical trials. The first live attenuated (recombinant) tetravalent dengue vaccine, Dengvaxia, produced by Sanofi Pasteur, has been licensed for use in some countries in Asia and Latin America. World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE) recommends that countries consider introduction of this dengue vaccine only in populations where epidemiological data indicate a high burden of disease. In order to maximize public health impact and cost effectiveness, the populations to be targeted for vaccination, as measured by seroprevalence, should be approximately 70% or greater in the age group targeted for vaccination.[11] Seroprevalence typically increases with age, and countries may choose to target vaccination to the youngest age (9 years or older) for which seroprevalence exceeds the recommended 70% threshold.[12] Since such data is not available for most of the endemic places in India, well designed serosurveys are recommended to support decision making for vaccine introduction for public health as well as for conducting clinical trials with dengue vaccines.
In view of these concerns, a stratified serosurvey was conducted in Pune city, Maharashtra, India. Pune is fast growing city, chosen under Smart Cities Mission scheme of the Prime Minister of India for speedy and orderly infrastructure development. The city has been experiencing seasonal, annual dengue outbreaks. It is pertinent to generate data on epidemiological determinants including disease burden estimates for proper planning of dengue management.
Pune, the second largest city in the state of Maharashtra after Mumbai and the seventh most populous city in the country is situated 560 meters above sea level on the Deccan plateau. Pune is the administrative headquarters of Pune district and is one of the fastest growing cities in the Asia-Pacific region.
A cross sectional, stratified, facility based, multistage cluster sampling was conducted in Pune city between May 4 and June 27, 2017, following the principles of WHO guidelines.[12] The dengue season in this area is typically from July to December. The present survey was planned to capture activity of dengue from the previous 2016 dengue season. Medical clinics are the first contact point between febrile cases and health seeking facilities. In all 15 wards, a corporation clinic was chosen as first point for sampling. Additional 3 clinics of general practitioners were chosen in such a manner to provide fair representation to the ward. This ratio was based on assumption that about 25% of the primary healthcare in the city is provided by the corporation clinics and the rest by the private practitioners. Fig 1 shows approximate locations of the collection sites (health facility).
The data on dengue prevalence in Pune city were not available. However, dengue prevalence of 59% was reported from an urbanized village near Pune city.[16] Assuming that prevalence in Pune city will be higher than the adjoining urbanized village, for the purpose of sample size calculations we assumed 65% prevalence in Pune city. The minimum sample size of 1,396 participants was calculated under the assumption of 65% prevalence for dengue infection, α 5% error, Confidence level 95%. Accounting for the multistage sampling, the sample size considered a design effect of 4.0. Sample allocation to each ward and age groups was in proportion to the population of the ward and age group with respect to the Pune population. Allowing 5% additional samples to meet contingencies like insufficient sample, leakage and spoilage we targeted 1,465 samples. A team visited each health facility. Each non-febrile patient and/or the person accompanying them visiting the facility and resident of the same ward were invited to participate in the study. The willing persons were enrolled until the target sample collection was achieved for that site. Each enrolled person was requested to provide a blood sample following administration of ethical consent/assent approved by the Institutional Ethics Committee of the University.
We collected blood samples from a total of 1,434 participants, 31 less than the original 1,465 sample target. About 5 mL blood was collected from each participants in anti-coagulant free vacutainer tubes (BD Bioscience) by trained phlebotomists and kept overnight at 4C. Serum samples were separated by centrifugation at 3,000 rpm for 10 minutes and stored at -80C.
As WHO recommends use of PRNT90 titers to minimize serum cross-reactivity with other dengue serotypes and flaviviruses prevalent in DENV endemic areas [12,18], we opted for PRNT90 method for this study. Due to resource constraint, we decided to process 120 indirect ELISA positive samples for PRNT. The selection of samples was based on Panbio units of IgG-positives (Indirect ELISA) arranged at the interval of 5 units and represented comparable proportions of total positives in each category.
795a8134c1